[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"appendiceal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:appendiceal-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,84,119,144,167,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100427519","phase-1-individual-response-to-hyperthermic-intraperitoneal-chemotherapy-hipec-treatment-of-peritoneal-carcinomatosis-from-peritoneal-mesothelioma-or-atypical-mesothelial-proliferation-or-from-ovarian-colorectal-or-appendiceal-histologies-100427519",false,"NCT04847063","Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries","* INCLUSION CRITERIA:\n* Confirmation of peritoneal carcinomatosis from peritoneal mesothelioma or atypical mesothelial proliferation, or from appendiceal, colorectal, or ovarian, histologies by the Laboratory of Pathology, NCI.\n* Measurable or evaluable disease as defined by RECIST v1.1. criteria and\u002For by peritoneal carcinomatosis index (PCI) score.\n* Participants must be assessed to be able to undergo optimal cytoreduction (i.e., completeness of cytoreduction score of 1 or 0) with laparoscopically assessed PCI score threshold as indicated below:\n\n  * Primary Histology: Appendiceal\u002FColorectal\u002FOvarian \u002F PCI Cutoff for Eligibility: Total Score \\\u003C 20 (out of 39 possible points)\n  * Primary Histology: Mesothelioma or atypical mesothelial proliferation \u002F PCI Cutoff for Eligibility: Total Score \\\u003C= 30 (out of 39 possible points)\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C= 1 (Karnofsky \\>= 80%).\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count \\>= 1,000\u002FmcL\n  * Platelets \\>= 75,000\u002FmcL\n  * Total bilirubin within \\\u003C=1.5x institutional upper limit of normal (ULN)\n  * AST (SGOT)\u002F ALT (SGPT) \\\u003C= 3x institutional upper limit of normal (ULN), or \\\u003C= 5.0x ULN in participants with liver metastases (only)\n  * Creatinine within normal institutional limits\n\nOR\n\n--Creatinine clearance \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal calculated using eGFR.\n\n* Because therapeutic agents used in this trial are known to be teratogenic, individuals of child-bearing potential (IOCBP) and individuals who are able to father a child must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 180 days after last study treatment.\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n* Ability and willingness of the participant to co-enroll on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors .\n\nEXCLUSION CRITERIA:\n\n* Participants with known extra-abdominal metastatic disease from the participant s appendiceal, colorectal, ovarian, or peritoneal mesothelioma primary.\n* Participants who have received intraperitoneal chemotherapy or other anti-cancer therapy within the last 4 weeks prior to the start of study treatment.\n* Participants who have undergone major surgery within the last 12 weeks prior to the start of study treatment.\n* History of allergic reactions attributed to platinum-containing compounds.\n* History of dihydropyrimidine dehydrogenase deficiency (only participants with appendiceal or colorectal cancer).\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant individuals are excluded from this study because the protocol involves major abdominal surgery and chemotherapeutic agents with the potential for teratogenic or abortifacient effects. Note: Due to an unknown but potential risk for adverse events in nursing infants secondary to treatment of the participant, nursing (including breastfeeding) should be discontinued if the participant is undergoing treatment (i.e., nursing participants must agree to discontinue nursing activities).\n* HIV-positive participants with detectable viral load despite antiretroviral therapy are ineligible because of participants increased risk of lethal infections when treated with marrow-suppressive therapy. HIV-positive participants who have undetectable viral load on antiretroviral therapy may be considered for this study only after consultation with a NIAID physician.","ALL","18 Years","120 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nCytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve the results of CRS with HIPEC treatment on these tumors by choosing the chemotherapy drugs used in HIPEC.\n\nObjective:\n\nTo see if HIPEC after CRS can be improved, using either a model called the SMART (Sustained Microenvironment for Analysis of Resected Tissue) System or using 3-D cell culture (organoid) models, in order to test different chemotherapy drugs on tumors that were surgically removed prior to HIPEC treatment (these models are not attached to the body) versus tumors that were treated with HIPEC while still inside the body before being immediately surgically removed.\n\nEligibility:\n\nAdults ages 18 and older who have peritoneal carcinomatosis that cannot be fully removed safely with surgery.\n\nDesign:\n\nParticipants will be screened with:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests\n\nElectrocardiogram (EKG)\n\nComputed tomography (CT) scan\n\nOther imaging scans, as needed\n\nTumor biopsy, if needed\n\nLaparoscopy (small cuts are made in the abdomen, and a tube with a light and a camera is used to see the organs in the abdomen), if needed\n\nParticipants will enroll in NIH protocol #13C0176. This allows their tumor samples to be used in future research.\n\nSome screening tests may be repeated in the study.\n\nParticipants will have CRS. As many of their visible tumors will be removed as possible during surgery except for a few specific tumors left to receive the HIPEC treatment. Then they will receive HIPEC and the remaining tumors will be immediately removed. Participants will be in the hospital for 7-21 days after this surgery (CRS with HIPEC).\n\nParticipants will give tumor, fluid samples (from the abdomen during surgery), blood, saliva, cheek swab, and stool for research. They will complete surveys about their health and quality of life.\n\nParticipants with peritoneal mesothelioma (mesothelioma primary only) will have genetic (DNA) testing to determine clinical (CLIA level) germline BAP1 status for research use.\n\nParticipants will have follow-up visits for up to 5 years from CRS with HIPEC.\n\nIf there is disease progression, participants may have CRS with HIPEC again. Participants will then have follow-up visits for up to 5 years from the date of last CRS with HIPEC.\n\n...",[27,28,29,30,31,32,33],"Peritoneal Mesothelioma","Peritoneal Carcinomatosis","Ovarian Cancer","Gastrointestinal Cancer","Appendiceal Cancer","Atypical Mesothelial Proliferation","Colorectal Cancer",[35,36,37,38,39,40,41,42],"cytoreduction","organoid model","cell culture model","SMART System","Peritoneal Metastasis","necrosis","Ki-67","cytoreductive surgery (CRS)","RECRUITING","2026-07-01",{"date":46,"type":47},"2026-07-02","ACTUAL",{"date":49,"type":47},"2021-10-19",{"date":51,"type":21},"2034-12-30",{"name":53,"class":54},"National Cancer Institute (NCI)","NIH",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":55},"100523866","locally-ablative-therapy-for-oligo-progressive-gastrointestinal-malignancies-livelong-100523866","NCT06101277","Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)","LIVELONG","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed cancers:\n\n   1. Cohort A: (Cohort removed in protocol version 4.0)\n   2. Cohort B: Small bowel\n   3. Cohort C: Pancreatic and ampullary, colorectal, and appendiceal\n   4. Cohort D: (Cohort removed in protocol version 4.0)\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":64,"type":21},300,[66],"NA","This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.",[69,33,31,70,71,72,73,74],"Small Bowel Cancer","Biliary Cancer","Gall Bladder Cancer","Intrahepatic Cholangiocarcinoma","Extrahepatic Cholangiocarcinoma","Oligoprogressive","2026-06-30",{"date":46,"type":47},{"date":78,"type":47},"2023-10-05",{"date":80,"type":21},"2039-09-15",{"name":82,"class":83},"University of California, Davis","OTHER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":55},"100639738","molecular-profiling-for-risk-stratification-in-appendiceal-cancer-100639738","NCT07587268","Molecular Profiling for Risk Stratification in Appendiceal Cancer","Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer","Inclusion Criteria:\n\n* Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.\n* Availability of archived tumor tissue suitable for molecular profiling.\n* Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.\n* Availability of relevant clinicopathologic data.\n* Availability of survival or follow-up information when applicable.\n* Age 18 years or older at diagnosis or tissue collection.\n\nExclusion Criteria:\n\n* Insufficient tissue quantity or quality for molecular profiling.\n* Inadequate DNA or RNA quality for sequencing or molecular assay preparation.\n* Missing essential clinicopathologic information required for analysis.\n* Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.\n* Patients who do not meet institutional review board or consent requirements, if applicable.",{"count":92,"type":21},400,"OBSERVATIONAL","This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.",[31,96],"Appendiceal Adenocarcinoma",[98,99,100,101,102,103,104,105,106,107,108,109],"Appendiceal cancer","Appendiceal adenocarcinoma","DNA methylation","m6A modification","Multi-omics","MeRIP-seq","Histologic grade;","Epigenomics","Epitranscriptomics","Molecular subtype","Risk stratification","Prognostic biomarker","2026-06-25",{"date":112,"type":47},"2026-06-29",{"date":114,"type":47},"2026-05-01",{"date":116,"type":21},"2027-01-01",{"name":118,"class":83},"City of Hope Medical Center",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":55},"100615328","a-feasibility-study-of-mass-based-response-drug-screening-to-guide-personalized-hyperthermic-intraperitoneal-chemotherapy-for-high-grade-appendiceal-and-colorectal-adenocarcinoma-with-peritoneal-metastasis-100615328","NCT07291180","A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis","Inclusion Criteria:\n\n* Has histologically confirmed peritoneal metastases with primary diagnosis of AJCC 8th Edition Stage IV\n\n  1. Appendiceal adenocarcinoma (moderately\u002Fpoorly differentiated, and\u002For signet ring cell tumors)\n  2. Colorectal adenocarcinoma\n  3. Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary\n* Limited or no extraperitoneal metastases (any of the below)\n\n  a) Any extraperitoneal metastases must be limited, stable and treatable\n* Has adequate organ function, as described below; all screening laboratory tests should be performed within 30 days prior to the first HIPEC\n* Expected survival at the time of first HIPEC is greater than 3 months\n* Exhibits unresectable disease (bowel or mesenteric involvement) or PCI \\> 19\n\nDemographics\n\n* Adult patient at least 18 years of age at the time of signing informed consent and less than 81 years of age at the time of signing informed consent.\n* Has an ECOG performance status score of 0-2.\n\nMale Participants\n\n* A male participant must agree to use contraception (barrier birth control, abstinence) during the treatment period and for at least 95 days following completion, corresponding to time needed to eliminate any study intervention(s), and refrain from donating sperm during this period.\n\nFemale Participants\n\n* A female participant of childbearing age is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception (hormonal, barrier birth control, or abstinence). Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nInformed Consent\n\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for FBR. However, the participant may participate in the main study without participating in FBR.\n\nAlternative Eligibility\n\n* In addition to the criteria above, if a patient has undergone less than 8 rounds of chemotherapy at another institution (prior to initial diagnostic laparoscopy) and has not undergone radiation, ablative procedures, or cytoreductive surgery, then they are still eligible to enter the study at the second diagnostic laparoscopy step\n\nExclusion Criteria:\n\n* Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Has a known allergy to medications used in this study. Note: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.\n* Has hypoxia as defined by pulse oximeter reading \\\u003C92% at rest or requires intermittent or chronic supplemental oxygen.\n* No concurrent malignancy that may interfere with the study aims at the discretion of the investigator.\n\nNote: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n\n* Has known significant extraperitoneal metastasis.\n* Has creatine clearance \\\u003C60 mL\u002Fm\\^2 per the Cockcroft-Gault formula\n* Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure. Medially controlled arrhythmia stable on medication is permitted.\n* Has poorly controlled hypertension defined as SBP ≥150mmHg and\u002For DBP ≥90mmHg.\n* Has moderate to severe hepatic impairment (Child-Pugh B or C).\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.\n* Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (severe dysphasia, bowel obstruction, malabsorption).\n* Has progressive disease following the first 3 months of systemic chemotherapy prior to HIPEC who is not in a stable condition to continue with the trial.\n\nPrior\u002FConcomitant Therapy\n\n* Has received radiation, ablative procedures, cytoreductive surgery, or systemic therapy including chemotherapy to treat metastatic disease within 3 months of initial laparoscopy.\n\nDiagnostic Assessments\n\n* Has an active infection requiring systemic therapy.\n* Has a known active TB\u002F COVID infection.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study intervention.\n* Has a known history of poorly controlled HIV infection despite anti-retroviral therapy.\n* Has a known history of HBV (defined as HBsAg reactive) or known active HCV (defined as HCV RNA \\[qualitative\\] is detected) infection that is poorly controlled.\n\nNote: Testing for HBV and HCV is only required if mandated by the local health authority.\n\nOther Exclusions\n\n* Inability to receive chemotherapy due to medical\u002Finsurance reasons.\n* Requires emergency surgery due to bleeding, perforation, or obstruction.\n* Has undergone previous iterative intraperitoneal therapy.\n* Has contraindication to chemotherapy of choice.","81 Years",{"count":127,"type":21},20,[66],"This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).",[31,131,132],"Colorectal Adenocarcinoma","Peritoneal Metastases",[31,131,132,134],"Iterative Hyperthermic Intraperitoneal Chemotherapy (IHIPEC)","2026-06-17",{"date":137,"type":47},"2026-06-22",{"date":139,"type":47},"2026-02-17",{"date":141,"type":21},"2027-12",{"name":143,"class":83},"Yale University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":55},"100602503","phase-4-intraoperative-imaging-of-gastrointestinal-malignancies-using-pafolacianine-cytalux-100602503","NCT07124351","Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)","Inclusion Criteria:\n\n1. Patients 18 years of age and older of any sex.\n2. Have a primary diagnosis, or a high clinical suspicion, of gastroesophageal adenocarcinoma based on CT (computed tomography)\u002FPET (positron emission tomography) or other imaging (Cohort 1) or diagnosis of appendiceal adenocarcinoma with a high clinical suspicion of peritoneal carcinomatosis (Cohort 2).\n3. Have an indication for surgical intervention for gastroesophageal tumor resection or diagnostic laparoscopy for assessment of peritoneal disease burden.\n4. Willingness to stop the use of folate, folic acid, or folate-containing supplements within 48 hours before administration of CYTALUX.\n5. Willingness of research participant to give written informed consent.\n\nExclusion Criteria:\n\n1. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject.\n2. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.\n3. History of allergy to any of the components of CYTALUX™ (pafolacianine) injection.\n4. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule.\n5. Known sensitivity to fluorescent light.\n6. Women of childbearing potential who are pregnant or plan to become pregnant during the study.",{"count":151,"type":21},15,[153],"PHASE4","This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).",[30,156,157,31],"Gastric Cancer","Esophageal Cancer","2025-09-09",{"date":160,"type":47},"2025-09-15",{"date":162,"type":47},"2025-09-05",{"date":164,"type":21},"2026-09",{"name":166,"class":83},"Cedars-Sinai Medical Center",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":175,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":178,"conditions":179,"keywords":193,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":55},"100495686","genetics-of-appendix-cancer-study-100495686","NCT05734430","Genetics of Appendix Cancer Study","Genetics of Appendix Cancer: The GAP Study","GAP","Inclusion Criteria:\n\nGAP Social\n\n* Known diagnosis of appendix cancer in the United States\n* Mentally and physically able to consent and participate in the study\n\nGAP Vanderbilt\n\n* Known diagnosis of appendix cancer\n* Diagnosed by and\u002For consulting with a physician\u002Fclinical provider participating in the GAP Study\n* Mentally and physically able to consent and participate in the study\n\nGAP Parent\n\n* Biological parents (mother and\u002For father) of individuals actively participating in the GAP Study\n* Residing in the United States\n* Mentally and physically able to consent and participate in the study\n\nExclusion Criteria:\n\n* Women pregnant at the time of consent\n* Prisoners\n* Unable to provide informed consent\n* Unable to read, write, or complete questionnaires in English",true,{"count":177,"type":21},700,"The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix\u002Fappendiceal cancer who are ages 18+ years.",[180,31,181,182,96,183,184,185,186,187,188,189,190,191,192],"Appendix Cancer","Appendiceal Neoplasms","Appendiceal Mucinous Neoplasm","Appendiceal Carcinoid Tumor","Appendiceal Neoplasm Malignant Secondary","Appendix Adenocarcinoma","Appendix Mucinous Neoplasm","Appendix Tumor","Appendix Cancer Metastatic","Appendix NET","Low-Grade Appendix Mucinous Neoplasm","High Grade Appendix Mucinous Neoplasm","High Grade Appendix Mucinous Adenocarcinoma",[194],"Genetics","2025-04-15",{"date":197,"type":47},"2025-04-18",{"date":199,"type":47},"2022-11-11",{"date":201,"type":21},"2034-11",{"name":203,"class":83},"Andreana Holowatyj, PhD, MSCI",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":55},"100467286","molecular-characterisation-of-appendiceal-cancer-100467286","NCT05364788","Molecular Characterisation of Appendiceal Cancer","Characterisation of Appendiceal Cancer by Genomic and Transcriptomic Analysis and Correlation With Clinical Outcomes","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases,\n2. have had cytoreductive surgery\n3. have availability of archival tumour tissue\n\nExclusion Criteria:\n\n* None",{"count":212,"type":21},100,"Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases, have had cytoreductive surgery, have availability of archival tumour tissue and have consented to our institutional biobank program or have a waiver of consent for deceased patients who have not had the opportunity to provide biobank consent (requested at the time of ethics review). Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.",[31],"2024-12-31",{"date":217,"type":47},"2025-01-01",{"date":219,"type":47},"2024-02-04",{"date":221,"type":21},"2025-07-03",{"name":223,"class":83},"The Christie NHS Foundation Trust"]